Advertisement
BMC Medicine volume 20, Article number: 487 (2022)
31
1
Metrics details
Sacubitril/valsartan and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) therapies were reported to affect glycaemic control and the development of diabetes mellitus (DM), but the findings are inconsistent. We examined the evidence for the effects of sacubitril/valsartan and ACEI/ARB in DM by conducting a meta-analysis.
The Cochrane Central Register of Controlled Trials (The Cochrane Library), Embase, PubMed, and ClinicalTrials.gov were searched for data from randomised clinical trials (RCTs) that evaluated the efficacy of sacubitril/valsartan and ACEI/ARB in patients, as of May 25, 2022. Patients were grouped by their disease background at baseline. The main outcomes were the number of new-onset DM and hypoglycaemia, elevated glycaemia, inadequate DM control, diabetes treatment, and diabetic complications, from baseline to the end of the trials. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (ROB 2). The quality of the evidence was evaluated according to the Recommendations for Assessment, Development, and Evaluation guidelines. The meta-analysis of the incidence of various outcomes was conducted using fixed or random effects models. The results are expressed as binary risk, 95% confidence interval (CI), and relative risk (RR). The Mantel-Haenszel method and Z test were used to determine the overall results and determine the significance of the RR.
This study included 31 RCTs and 86,809 subjects. Compared with placebo, sacubitril/valsartan treatment significantly reduced the risk of new-onset DM among all patients (RR = 0.78, 95% CI: 0.64–0.95), patients with heart failure (HF) (RR = 0.24, 95% CI: 0.12–0.48), HF with reduced ejection fraction (HFrEF) (RR = 0.24, 95% CI: 0.12–0.50), and HF with preserved ejection fraction (HFpEF) (RR = 0.54, 95% CI 0.34–0.85). In contrast, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among all patients (RR = 1.91, 95% CI: 1.05–3.47), patients with not all-DM (defined as part of the study population having DM at baseline) (RR = 5.71, 95% CI: 2.02–16.21), and patients with HFpEF (RR = 7.06, 95% CI: 2.10–23.76). Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12–3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51–8.55, p = 0.004). Compared with placebo, ACEI/ARB treatment did significantly reduce the risk of new-onset DM among all patients (RR 0.85, 95% CI 0.77–0.93, p = 0.0007) and patients with not all-HF (defined as part of the study population having HF at baseline) (RR 0.87, 95% CI 0.82–0.93, p<0.0001) and HFpEF (RR 0.60, 95% CI 0.44–0.83, p = 0.002), diabetes complications among patients with non-HF (/not all-DM) (RR 0.87, 95% CI 0.76–0.99, p = 0.04), and subsequent diabetes treatment among patients with new-onset DM (RR 0.70, 95% CI 0.58–0.84, p = 0.0002) and significantly increased the risk of hypoglycaemia among patients with not all-DM (RR 2.06, 95% CI 1.172–3.61, p = 0.01).
The results of our study, especially in reducing glycaemia and new-onset DM, revealed that sacubitril/valsartan had a positive effect on the control of glycaemia and the development of DM. ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan. The above effects varied across diseases but the evidence was strongest in patients with HF.
CRD42022336311.
Peer Review reports
Does sacubitril/valsartan or ACEI/ARB have an effect on glycaemia and the development of diabetes?
In this meta-analysis of 31 randomised controlled trials that included 86,809 patients, compared with placebo, sacubitril/valsartan treatment significantly reduced the risk of new-onset diabetes (relative risk [RR] = 0.78, 95% confidence interval [CI] 0.64–0.95) and increased the risk of hypoglycaemia (RR = 1.91, 95% CI: 1.05–3.47); ACEI/ARB treatment significantly reduced the risk of new-onset diabetes (RR = 0.85, 95% CI: 0.77–0.93) and diabetes complications among patients with non-HF (RR = 0.87, 95% CI: 0.76–0.99) and diabetes treatment among patients with new-onset diabetes (RR = 0.70, 95% CI: 0.58–0.84) and increased the risk of hypoglycaemia among patients with not all-diabetes (RR = 2.06, 95% CI: 1.17–3.61).
Sacubitril/valsartan and ACEI/ARB had a positive effect on the control of glycaemia and the development of diabetes.
Diabetes mellitus (DM) is one of the major public health problems in the world today [1]. The latest global estimates from the International Diabetes Federation indicate that 537 million adults had DM in 2021, and that number is expected to increase to 643 million by 2030 [2]. DM often coexists with multiple diseases, especially in patients with heart failure (HF), in which the prevalence of diabetes is as high as 35–40% [3], and vice versa, leading to an adverse interactive effect on prognosis. The dual prevalence of DM and HF urgently requires effective treatments to address the increased burden in patients [4].
The role of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB) in glycaemic control and the development of diabetes has long been noted, but the mechanisms for improving glucose tolerance and insulin sensitivity by inhibiting the renin-angiotensin system are complex and unclear. Relevant trials [5,6,7,8] showed that ACEI/ARB could reduce new-onset diabetes and lower blood glucose levels compared with placebo. However, most outcomes other than new-onset diabetes did not reach statistical significance, the results were not uniform, and the research indicators of DM were relatively single.
The results of the PARADIGM-HF trial led to a landmark drug, sacubitril/valsartan, for the treatment of HF. The post hoc analysis of this trial suggested that sacubitril/valsartan treatment improved glycaemic control and conferred additional metabolic benefit [9]. Related preclinical studies also showed that dual ACE-neprilysin inhibitors could improve insulin sensitivity and improve glucose metabolism in obese rats and patients with insulin resistance [10,11,12]. The possible mechanisms for the role of sacubitril/valsartan in DM, in addition to the related effects of inhibiting the renin-angiotensin system, include decreasing the degradation of active peptides that can lower glycaemia by inhibiting neprilysin, and improving glucolipid metabolism and insulin resistance by consuming excessive energy by increasing natriuretic peptides [13,14,15]. Nevertheless, no specialised study on the mechanism and effects of sacubitril/valsartan in DM has been conducted.
Evaluating the role of sacubitril/valsartan and ACEI/ARB in DM, especially among patients with DM combined with HF, is a clinically meaningful issue. The purpose of this meta-analysis was to explore the effect of sacubitril/valsartan on glycaemia and the development of DM by analysing DM-related outcomes (new-onset DM, hypoglycaemia, elevated glycaemia, inadequate control DM, diabetes complications, and diabetes treatment) in randomised controlled trials (RCTs) and provide an updated analysis of the role of ACEI/ARB in treating diabetes. Furthermore, the results of this meta-analysis will help to provide physicians with information related to glycaemia and diabetes for use when treating patients with sacubitril/valsartan or ACEI/ARB.
All included studies were published without moral and informed consent disputes.
All procedures strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The application of this systematic review protocol for registration has been registered in the PROSPERO database (International Prospective Register of Systematic Reviews, https://www.crd.york.ac.uk/prospero), register number: CRD42022336311. The review method registered and updated in PROSPERO is described in Additional file 1 [16]. The evaluation of the quality of evidence was accorded to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guideline.
We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library), Embase, PubMed, and ClinicalTrials.gov, the four major medical databases containing the majority of medical research literature, as of May 25, 2022. Two reviewers independently performed literature searches using search strategies designed by author RXW (the retrieval strategies are described in Additional file 2: Tables S1-S4). Publication date and language restrictions were not applied, and the reference lists of the related articles were also used to supplement the search terms. In addition, we use the appropriate filters (Additional file 2: Tables S1-S4). Duplicate articles were removed using reference manager software. Three reviewers independently identified the eligible studies according to pre-formulated inclusion and exclusion criteria (Additional file 2: Table S5). We included RCTs of adults in this meta-analysis if the control group was treated with ACEI/ARB/placebo and the experimental group was treated with sacubitril/valsartan or the control group was given a placebo and the experimental group was treated with ACEI/ARB.
Two reviewers independently extracted data from the RCTs that met the criteria and the guidelines in Cochrane Reviewer’s Handbook, and all authors discussed the results in the event of discrepancies. The research data were retrieved from the original published manuscript or the results in ClinicalTrials.gov. The following data were extracted from each trial: (1) name of the trial, author, and registration number; (2) year of publication; (3) number of participants enrolled; (4) characteristics of the participants at baseline, including DM status, age, and gender; (5) the drug used in the control group; (6) study duration; (7) main outcomes; and (8) the number of participants with new-onset DM, hypoglycaemia, hyperglycaemia, inadequate DM control, diabetes treatment, and diabetes complications from baseline to the end of the study.
Two researchers separately assessed the risk of bias for each qualified trial using the revised Cochrane risk-of-bias tool for randomized trials (ROB 2) and compiled a risk-of-bias table as described in the Cochrane Handbook [17].
We used the GRADE principles to assess the quality of the evidence in this meta-analysis. The quality of the evidence was graded as very low, low, moderate, or high by measuring the risk of bias, inconsistency, indirectness, imprecision, and publication bias.
A number of adverse reactions related to DM listed in the results of trials include new-onset DM, hypoglycaemia, elevated glycaemia, inadequate control DM, diabetes complications, and diabetes treatment, from baseline to the end of the trials. Among these, the number of new-onset DM cases and the remaining indicators reflected the effect of the drug on the development of diabetes and glycaemic control, respectively.
The data were analysed using Review Manager 5.4 and Stata 17.0. Direct comparisons of sacubitril/valsartan and ACEI/ARB groups and between ACEI/ARB and placebo groups were performed using Review Manager. A network meta-analysis of sacubitril/valsartan and placebo groups was performed using the ACEI or ARB group as an intermediate group and the “Network” program of Stata. Subgroup analysis was performed according to whether the patients had DM or HF (the included studies may have used different criteria for HF, and we did not use a standardised definition for HF) at baseline. Sensitivity analysis and publication bias detection were performed using Stata, and I2 was used to assess heterogeneity. An I2 value of > 50% or a corresponding p-value of < 0.05 was considered to indicate heterogeneity among the studies. In that case, we used a random model and performed meta-regression and subgroup analysis. An I2 of ≤ 50% and a corresponding p-value of ≥ 0.05 were considered to indicate no obvious heterogeneity in the results, and a fixed model was used [18]. Due to the lack of direct comparison, there was no need to test for inconsistency in the network meta-analysis. The data were extracted from each trial and expressed as binary risk. The 95% confidence interval (CI) and relative risk (RR) were used in the synthesis or presentation of the results. The Mantel-Haenszel method and the Z test were used to determine the overall results and the significance of the RR. A p-value of < 0.05 was considered statistically significant. All results were consistent with the PRISMA (Additional file 3) and meta-analysis guidelines [19].
Funnel plots and Egger’s test [20] were used to detect publication bias using Stata, as was sensitivity analysis.
Initially, 21,836 possible articles or studies were identified, and 2973 possible articles were left after filtering and removing duplicates. The remaining articles were judged by the three researchers according to the inclusion and exclusion criteria. Finally, 31 RCTs including 86,809 subjects were included in the analysis. The flow chart of study selection is shown in Additional file 2: Fig. S1.
The detailed characteristics of the 31 trials [6,7,8, 21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45] are shown in Table 1, of which, most were large, multi-centre clinical studies, with 13 and 5 trials aimed at patients with HF and DM, respectively. In the patients with HF, the EF range for HFrEF was defined as an EF of ≤ 40% or 35%. HFpEF was defined as an EF of ≥ 40% or 45%. The total number of subjects was 86,809 and the follow-up period ranged from 8 weeks to 6.5 years. Randomised assignments were made using computer-generated random numbers in most of the trials and pre-specified outcomes were reported in all trials. Only one study (TRAFIC) did not use blinding.
The quality assessment of the included studies is presented in Additional file 4: Figs. S1-S2. One (0.5% weighting of all studies) RCT included in this meta-analysis revealed a high risk of bias when assessed by ROB 2, whereas twenty-six (81.4% weighting) RCTs raised some concerns and four (18.1% weighting) RCTs revealed a low risk of bias. This was mainly due to the fact that the definition and standard measures of the outcomes we studied were not elaborated in part of the studies.
The meta-analysis results and grades of the quality of the evidence are summarised in Table 2, in which the results with a statistical difference are shown in Figs. 1, 2, and 3.
The effect of sacubitril/valsartan or ACEI/ARB on new-onset DM
The effect of sacubitril/valsartan or ACEI/ARB on hypoglycaemia
The effect of sacubitril/valsartan or ACEI/ARB on diabetes complications or diabetes treatment
The data in this part of the study were all derived from patients with non-DM at baseline. Between the two groups, there was no difference in reduction in the risk of new-onset DM among all patients (RR = 0.91, 95% CI: 0.76–1.09, p = 0.32) and patients with not all-HF (defined as part of the study population having HF at baseline) (RR = 2.95, 95% CI: 0.31–28.00, p = 0.35), HF (RR = 0.90, 95% CI: 0.75–1.08, p = 0.27), HFrEF (RR = 0.90, 95% CI: 0.72–1.13, p = 0.37), and HF with preserved ejection fraction (HFpEF) (RR = 0.89, 95% CI: 0.64–1.25, p = 0.51). There was also no difference in the risk of new-onset DM between patients treated with sacubitril/valsartan and ACEI (RR = 0.91, 95% CI: 0.73–1.14, p = 0.41) or ARB (RR = 0.90, 95% CI: 0.65–1.24, p = 0.51) (Additional file 4: Fig. S3).
Compared with ACEI/ARB, sacubitril/valsartan treatment did significantly increase the risk of hypoglycaemia among patients with HF (/not all-DM [defined as part of the study population having DM at baseline]) (RR = 1.85, 95% CI: 1.12–3.06, p = 0.02) and HFpEF (RR = 3.59, 95% CI: 1.51–8.55, p = 0.004), as was the comparison of sacubitril/valsartan and ARB (RR = 2.72, 95% CI: 1.18–6.27, p = 0.02) treatment, but the increase in the risk of hypoglycaemia among patients with HFrEF (RR = 1.18, 95% CI: 0.62–2.26, p = 0.61) was no significant between-group difference, as was the comparison of sacubitril/valsartan and ACEI (RR = 1.26, 95% CI: 0.65–2.46, p = 0.49) treatment (Additional file 4: Fig. S4).
Between the two groups, there was no difference in reduction in the risk of elevated glycaemia among all patients (RR = 0.81, 95% CI: 0.52–1.26, p = 0.35) and patients with no all-HF (RR = 0.59, 95% CI: 0.28–1.23, p = 0.16), HF (RR = 0.96, 95% CI: 0.56–1.66, p = 0.88), HFrEF (RR = 1.84, 95% CI: 0.68–4.97, p = 0.23), and HFpEF (RR = 0.70, 95% CI: 0.35–1.38, p = 0.30). There was also no difference in the risk of elevated glycaemia between patients treated with sacubitril/valsartan and ACEI (RR = 1.81, 95% CI: 0.61–5.39, p = 0.29) or ARB (RR = 0.70, 95% CI: 0.43–1.14, p = 0.15) (Additional file 4: Fig. S5).
All data of DM inadequate control came from patients with HF at baseline. Compared with ACEI/ARB, sacubitril/valsartan treatment did not significantly reduce the risk of DM inadequate control among patients with HF (RR = 0.73, 95% CI: 0.29–1.82, p = 0.50), HFrEF (RR = 0.79, 95% CI: 0.31–2.07, p = 0.64), and HFpEF (RR = 0.34, 95% CI: 0.01–8.82, p = 0.51), as were the comparison of sacubitril/valsartan and ACEI (RR = 0.79, 95% CI: 0.31–2.07, p = 0.64) or ARB (RR = 0.34, 95% CI: 0.01–8.28, p = 0.51) treatment (Additional file 4: Fig. S6).
All data of diabetic complications came from patients with HF at baseline. Compared with ACEI/ARB, sacubitril/valsartan treatment did not significantly reduce the risk of diabetic complications among patients with HF (RR = 0.80, 95% CI: 0.49–1.32, p = 0.38), HFrEF (RR = 0.91, 95% CI: 0.49–1.69, p = 0.77), and HFpEF (RR = 0.64, 95% CI: 0.28–1.47, p = 0.29), as were the comparison of sacubitril/valsartan and ACEI (RR = 0.95, 95% CI: 0.50–1.81, p = 0.88) or ARB (RR = 0.64, 95% CI: 0.28–1.47, p = 0.29) treatment (Additional file 4: Fig. S7).
Compared with ACEI/ARB, sacubitril/valsartan treatment did not significantly reduce the subsequent use of oral antihyperglycaemic or insulin treatment among patients with new-onset DM (RR = 1.17, 95% CI: 0.82–1.66, p = 0.39) (Additional file 4: Fig. S8).
The data in this part of the study were all derived from patients without DM at baseline. Between the two groups, there were significant differences in reduction in the risk of new-onset DM among all patients (RR = 0.85, 95% CI: 0.77–0.93, p = 0.0007) and patients with not all-HF (RR = 0.87, 95% CI: 0.82–0.93, p < 0.0001) and those with HFpEF (RR = 0.60, 95% CI: 0.44–0.83, p = 0.002), as were the comparison of ACEI (RR = 0.79, 95% CI: 0.64–0.99, p = 0.04) or ARB (RR = 0.89, 95% CI: 0.83–0.95, p = 0.0003) and placebo treatment, but the reductions in the risk of new-onset DM among patients with non-HF (RR = 0.88, 95% CI: 0.75–1.02, p = 0.10), HF (RR = 0.53, 95% CI: 0.26–1.04, p = 0.07), and HFrEF (RR = 0.53, 95% CI: 0.14–1.97, p = 0.34) were no significant between-group difference (Additional file 4: Fig. S9).
Compared with placebo, ACEI/ARB treatment did significantly increase in the risk of hypoglycaemia among patients with not all-DM (RR = 2.06, 95% CI: 1.172–3.61, p = 0.01), but the increase in the risk of hypoglycaemia among all patients (RR = 1.06, 95% CI: 0.94–1.20, p = 0.33), and patients with non-HF (RR = 1.26, 95% CI: 0.85–1.87, p = 0.25), not all-HF (RR = 1.02, 95% CI: 0.90–1.16, p = 0.76), HFpEF (RR = 2.00, 95% CI: 0.86–4.66, p = 0.11), non-DM (RR = 1.10, 95% CI: 0.94–1.30, p = 0.23), DM (RR = 0.90, 95% CI: 0.73–1.10, p = 0.29), type 1 DM (T1DM) (RR = 0.82, 95% CI: 0.52–1.30, p = 0.41), and type 2 DM (T2DM) (RR = 0.89, 95% CI: 0.69–1.14, p = 0.35) were no significant between-group difference, as were the comparison of ACEI (RR = 1.01, 95% CI: 0.63–1.60, p = 0.98) or ARB (RR = 1.07, 95% CI: 0.94–1.21, p = 0.31) and placebo treatment (Additional file 4: Fig. S10).
Between the two groups, there was no significant difference in reduction in the risk of elevated glycaemia among all patients (RR = 0.89, 95% CI: 0.66–1.21, p = 0.46) and patients with non-HF (RR = 0.87, 95% CI: 0.58–1.31, p = 0.51), not all-HF (RR = 0.91, 95% CI: 0.55–1.50, p = 0.70), HFpEF (RR = 1.00, 95% CI: 0.29–3.45, p = 1.00), non-DM (RR = 1.01, 95% CI: 0.06–16.21, p = 0.99), no all-DM (RR = 0.90, 95% CI: 0.62–1.32, p = 0.60), DM (RR = 0.87, 95% CI: 0.52–1.46, p = 0.60), T1DM (RR = 0.65, 95% CI: 0.30–1.38, p = 0.26), and T2DM (RR = 1.16, 95% CI: 0.55–2.42, p = 0.70). There was also no difference in the risk of elevated glycaemia between patients treated with ARB (RR = 0.89, 95% CI: 0.66–1.21, p = 0.46) and placebo (Additional file 4: Fig. S11).
Compared with placebo, ACEI/ARB treatment did not significantly reduce the risk of DM inadequate control among all patients (RR = 0.82, 95% CI: 0.58–1.16, p = 0.26), non-HF (RR = 0.34, 95% CI: 0.03–3.22, p = 0.34), not all-HF (RR = 0.87, 95% CI: 0.60–1.24, p = 0.43), HFpEF (RR = 0.60, 95% CI: 0.14–2.50, p = 0.48), not all-DM (RR = 0.65, 95% CI: 0.22–1.89, p = 0.43), DM (RR = 0.85, 95% CI: 0.59–1.22, p = 0.37), T1DM (RR = 0.86, 95% CI: 0.40–1.85, p = 0.69), and T2DM (RR = 0.84, 95% CI: 0.56–1.28, p = 0.42), as was the comparison of ARB (RR = 0.82, 95% CI: 0.58–1.16, p = 0.26) and placebo treatment (Additional file 4: Fig. S12).
Compared with placebo, ACEI/ARB treatment did significant reduce the risk of diabetes complications among patients with non-HF (not all-DM) (RR = 0.87, 95% CI: 0.76–0.99, p = 0.04), as was the comparison of ACEI (RR = 0.85, 95% CI: 0.73–0.98, p = 0.03) and placebo treatment, but there were no significant difference in reduction in the risk of diabetes complications among all patients (RR = 0.90, 95% CI: 0.80–1.01, p = 0.08), patients with not all-HF (RR = 1.03, 95% CI: 0.77–1.37, p = 0.87), HFpEF (RR = 1.00, 95% CI: 0.35–2.84, p = 1.00), non-DM (RR = 0.34, 95% CI: 0.01–8.30, p = 0.51), DM (RR = 1.05, 95% CI: 0.78–1.41, p = 0.93), T1DM (RR = 1.05, 95% CI: 0.68–1.61, p = 0.82), and T2DM (RR = 1.05, 95% CI: 0.70–1.57, p = 0.81), as was the comparison of ARB (RR = 1.00, 95% CI: 0.82–1.23, p = 1.00) and placebo treatment (Additional file 4: Fig. S13).
Compared with placebo, ACEI/ARB treatment did significantly reduce the subsequent use of oral antihyperglycaemic treatment or insulin among patients with new-onset DM (RR = 0.70, 95% CI: 0.58–0.84, p = 0.0002) (Additional file 4: Fig. S14).
No suitable study on the direct comparison of sacubitril/valsartan and placebo groups was included. Therefore, network meta-analysis was performed on the sacubitril/valsartan and placebo groups using the ACEI or ARB group as an intermediate group (Additional file 2: Figs. S2-S7 for network diagram).
The data in this part of the study were all derived from patients without DM at baseline. Between the two groups, there were significant differences in reduction in the risk of new-onset DM among all patients (RR = 0.78, 95% CI: 0.64–0.95), patients with HF (RR = 0.24, 95% CI: 0.12–0.48), HFrEF (RR = 0.24, 95% CI: 0.12–0.50), and HFpEF (RR = 0.54, 95% CI: 0.34–0.85), but among patients with not all-HF (RR = 2.57, 95% CI: 0.27–24.42), there was no significant between-group difference (Additional file 4: Figs. S15-S19).
Compared with placebo, treatment with sacubitril/valsartan significantly increased the risk of hypoglycaemia among all patients (RR = 1.91, 95% CI: 1.05–3.47), patients with not all-DM (RR = 5.71, 95% CI: 2.02–16.21), and those with HFpEF (RR = 7.06, 95% CI: 2.10–23.76) (Additional file 4: Figs. S20-S22).
Compared with placebo, sacubitril/valsartan treatment reduced the risk of elevated glycaemia among all patients (RR = 0.61, 95% CI: 0.34–1.09), patients with not all-DM (RR = 0.59, 95% CI: 0.31–1.11), not all-HF (RR = 0.53, 95% CI: 0.22–1.30), and HFpEF (RR = 0.71, 95% CI: 0.17–2.97), but there was no significant between-group difference (Additional file 4: Figs. S23-S26).
Compared with placebo, sacubitril/valsartan treatment reduced the risk of DM inadequate control among all patients (RR = 0.29, 95% CI: 0.01–7.15) and patients with not all-DM (RR = 0.22, 95% CI: 0.001–6.37) and HFpEF (RR = 0.20, 95% CI: 0.01–6.74), but there was no significant between-group difference (Additional file 4: Figs. S27-S29).
Compared with placebo, sacubitril/valsartan treatment reduced the risk of diabetes complications among all patients (RR = 0.74, 95% CI: 0.44–1.25) and patients with not all-DM (RR = 0.73, 95% CI: 0.43–1.24) and HFpEF (RR = 0.66, 95% CI: 0.17–2.62), but there was no significant between-group difference (Additional file 4: Figs. S30-S32).
Compared with placebo, sacubitril/valsartan treatment reduced the subsequent use of oral antihyperglycaemic treatment or insulin among patients with new-onset DM (RR = 0.68, 95% CI: 0.43–1.10), but there was no significant between-group difference (Additional file 4: Fig. S33).
Only the heterogeneity of the studies on the effect of ACEI/ARB compared with placebo on new-onset diabetes was high (I2 = 55%) (Additional file 4: Fig. S9). Thus, regression analysis was performed on four variables, including the year of study publication, HF at baseline, whether the study was a multi-centre study, and the drug used in the intervention group. The results showed that a single-centre study was the reason for the heterogeneity of our study. When the variable was used in subgroup analysis, the study results did not change, and the heterogeneity of the two subgroups was low (Additional file 4: Fig. S9). Therefore, the results of our study were reliable.
Funnel plots were drawn for the studies that included more than nine trials. Only studies on the effect of ACEI/ARB versus placebo on new-onset diabetes or diabetes complications were used to make funnel plots (Additional file 2: Figs. S8-S9), which showed that there was no publication bias. Egger’s test was used to test for publication bias in studies that included more than four trials. All p-values were > 0.05, so no publication bias was found in the included studies.
Sensitivity analysis was performed using Stata, and the results showed that two studies could be highly sensitive (Additional file 2: Figs. S10-S20). After the one-by-one exclusion method, the two results were found to be stable and credible. Therefore, the sensitivity of all studies was low, and the results of the direct comparison were stable and credible.
Publication bias detection was performed using the method described above. The funnel plots (Additional file 4: Figs. S21-S25) showed possible publication bias in the results of the effect of sacubitril/valsartan compared with placebo on elevated glycaemia among all patients or patients with not all-DM. Egger’s test was used to test for publication bias in the above two studies as well as in other studies that did not lend themselves to funnel plotting. All p-values were > 0.05, so no publication bias was found in the included studies. Since no direct comparison studies of sacubitril/valsartan and placebo were included in the network meta-analysis, inconsistency and loop-loop inconsistency tests were not required.
The GRADE assessment indicated that the overall quality of the evidence was mostly moderate and high. Of the 22 outcomes that were statistically significant, eight had high-quality evidence, ten had moderate-quality evidence, and four had low-quality evidence. Especially, in the sacubitril/valsartan versus placebo comparison, the number of studies with high, moderate, and low-quality evidence for the seven outcomes with statistical differences was 3, 3, and 1, respectively. Indicating that the estimated meta-analysis effects were likely to be close to or similar to the actual effects.
The results of the HOPE study showed that ramipril was associated with a lower rate of newly diagnosed diabetes in high-risk populations [5, 37], as was valsartan in the Navigator study [36]. The CHARM study reported that candesartan appeared to prevent diabetes in patients with HF [7], while the results of three network meta-analysis [46,47,48] showed that ARB/ACEI were associated with the lowest rate of new-onset diabetes among patients treated with ACEI/ARB and placebo. However, in the DREAM study, a large prospective study specifically addressing the role of ACEI in diabetes, treatment with ramipril for 3 years did not significantly reduce the incidence of diabetes among people with impaired fasting glucose levels or impaired glucose tolerance [6]. In the DREAM study, ramipril significantly increased the rate of returning to normal blood glucose levels [6], and in the HOPE study [5, 37], ramipril treatment significantly reduced hemoglobinA1c (HbA1c) levels in the first and second years compared with placebo. However, at the study endpoint, the changes in HbA1c levels relative to baseline were the same in both groups. Ramipril also significantly reduced the rate of oral hypoglycaemic agent or insulin use in patients with diabetes [5, 37]. These study findings suggest that ACEI/ARB played a role in reducing new-onset diabetes as well as controlling blood glucose levels. However, the effects remain to be clarified.
A post hoc analysis of the PARADIGM-HF study [9] showed that sacubitril/valsartan significantly reduced HbA1c levels compared with enalapril in patients with combined HF with DM at baseline, with similar but not statistically significant effects in patients with combined HF with non-DM at baseline. Sacubitril/valsartan treatment significantly reduced initial insulin use and the proportion of patients using glucose-lowering drug treatment in patients with combined HF with DM at baseline. However, no similar differences were found in patients with new-onset diabetes. Sacubitril/valsartan treatment reduced the incidence of new-onset diabetes compared with enalapril, and hypoglycaemia (a lateral response to the glucose-lowering effect) occurred more often in diabetes patients treated with sacubitril/valsartan compared with enalapril (a lateral response to the glucose-lowering effect of sacubitril/valsartan). However, neither reached statistical significance. These results suggest that sacubitril/valsartan exerted better glycaemic control compared with ACEI, but the effect on new-onset diabetes compared with placebo remains unclear.
This study was conducted to explore the effect of sacubitril/valsartan on the development of DM according to differences in the incidence of new-onset DM, and the potential role of sacubitril/valsartan in glycaemic control reflected by the differences in the incidence of remaining outcomes (hypoglycaemia, elevated glycaemia, DM inadequate control, diabetic complications, and DM need treatment).
Compared with placebo, sacubitril/valsartan treatment significantly reduced the risks of new-onset DM in patients without DM and patients with HF, HFrEF, and HFpEF by 22%, 76%, 76%, and 46%, respectively, and significantly increased the risks of hypoglycaemia among all patients, patients without DM, and patients with HFpEF by 91%, 471%, and 606%, respectively, but reduced the risks of hyperglycaemia, inadequate DM control, diabetes complications, and diabetes treatment by 39%, 71%, 26%, and 32%, respectively, with no statistical difference. The results were similar in the subgroups.
Besides, compared with ACEI/ARB, sacubitril/valsartan treatment increased the risks of hypoglycaemia among patients with not all-DM, HF, HFpEF, and the comparison with ARB treatment by 85%, 85%, and 172%, respectively, with statistically significant differences, but reduced the risks of new-onset DM, elevated glycaemia, DM inadequate control, and diabetes complications by 9%, 19%, 27%, and 20%, respectively, with no significant difference. The results were similar in the subgroups.
Compared with placebo, ACEI/ARB treatment did significantly reduce the risks of new-onset DM among patients without DM and patients with not all-HF, HFpEF, and the comparison with ACEI or ARB by 15%, 13%, 40%, 21%, and 11%, respectively, diabetes complications among patients with not all-DM (/non-HF), and the comparison with ACEI by 13% and 15%, respectively, diabetes treatment among patients without DM by 30%, and significantly increased the risk of hypoglycaemia among patients with not all-DM by 106%, but reduced the risks of elevated glycaemia, DM inadequate control, and diabetes complications by 11%, 18%, and 11%, respectively, with no statistical difference.
Previous trials showed that the use of renin-angiotensin-aldosterone system (RAAS) inhibitor treatment could induce hypoglycaemia, improve blood glucose levels, and reduce the incidence of DM [49,50,51]. The specific mechanism of these effects is not clear, but the possible mechanisms include [52] increasing insulin secretion by decreasing the hepatic clearance of insulin, attenuating the pernicious effect of angiotensin II on the pancreas (such as vasoconstriction, apoptosis, and β-cell death), improving pancreatic blood flow [53], improving insulin resistance by enhancing adipocyte differentiation, and reducing inflammation to improve DM-related metabolism [46, 54] by inhibiting angiotensin II.
No direct studies have investigated the mechanism by which sacubitril/valsartan affects glycaemia. As a combined inhibitor of RAAS and neprilysin, the main mechanism of sacubitril/valsartan’s effect on glycaemia may be by inhibiting neprilysin. Neprilysin can decompose a variety of vasoactive peptides, including bradykinin, glucagon, glucagon-like peptide-1, insulin-B chain, vasoactive intestinal peptide, and other substances that play certain roles in glycaemia regulation [13]. Sacubitril/valsartan can decrease blood glucose levels by increasing glucose-lowering active peptides, especially glucagon-like peptide-1 and active peptides, which improve insulin sensitivity or islet function (such as bradykinin and plasma dipeptidyl peptidase 4) by inhibiting neprilysin. In addition, relevant studies showed that lower plasma natriuretic peptide (NP) concentrations were associated with insulin resistance and DM [55,56,57,58,59,60] possibly because reductions in NP lead to metabolic disturbances [14], especially in adipose tissue and skeletal muscle [61], whereas higher NP concentrations appear to have protective effects by reducing the risk of DM. As the main mechanism of the effect of sacubitril/valsartan in HF is by inhibiting NP degradation, this may be one of the important reasons why it prevents and improves DM. NP can improve glucose metabolism and insulin resistance by consuming excessive energy by increasing the oxidation of circulating free fatty acids [15], increasing the synthesis of adiponectin in adipocytes [62], inhibiting the secretion of pro-inflammatory cytokines by macrophages in adipose tissue [63], and promoting the transformation of white adipocytes into brown adipocytes [64, 65]. In addition, NP promotes beneficial metabolism by reducing hunger and ghrelin concentrations in circulating and increasing satiety in healthy individuals, which are beneficial for glycaemic control [66]. Finally, as sacubitril/valsartan can improve cardiac and renal function and thus affect the organs and tissues related to DM, these effects may explain why sacubitril/valsartan improves DM.
Our findings are similar to the post hoc analysis of the PARADIGM-HF study, which found that sacubitril/valsartan treatment significantly reduced the incidence of new-onset DM and increased hypoglycaemic events in patients with HF, suggesting a role for sacubitril/valsartan in controlling the development of diabetes and a possible role in lowering blood glucose levels. In addition, in the majority of cases, compared with ACEI/ARB or placebo, sacubitril/valsartan treatment reduced the incidence of new-onset DM, hyperglycaemia, inadequate DM control, diabetes complications, and diabetes treatment and increased the incidence of hypoglycaemia. These results also reflect the potential effectiveness of sacubitril/valsartan in treating diabetes in people with different co-morbidities, although statistical significance was not reached. Some additional findings were made in this study. Some differences in the effectiveness of treatment according to the study metrics, especially new-onset DM, hypoglycaemia, and hyperglycaemia, were seen in patients with different types of HF treated with sacubitril/valsartan. The biggest difference was in the risk of new-onset DM (HFpEF, RR 0.54 vs HFrEF, RR 0.24), hypoglycaemia (RR 3.59 vs RR 1.18), and hyperglycaemia (RR = 0.70 vs RR = 1.84). Sacubitril/valsartan treatment resulted in a higher proportion of hypoglycaemia in the HFpEF than in the HFrEF group (23/3699 vs 19/5040), and the control group data showed that ACEI/ARB treatment lowered the incidence of hypoglycaemia in the HFpEF group compared with the HFrEF group (6/3686 vs 16/5066), which suggested that the difference in the incidence of hypoglycaemia in different types of HF was not directly caused by the type of HF but by sacubitril/valsartan treatment. Furthermore, the proportion of inadequate DM control (0% vs 0.02%) and diabetes complications (0.02% vs 0.04%) was lower, and hypoglycaemia (0.06% vs 0.04%) was higher in the HFpEF than in HFrEF the group. Overall, sacubitril/valsartan treatment may be more effective in controlling glycaemia in patients with HFpEF than in patients with HFrEF. However, it should be noted that there was a lack of data comparing sacubitril/valsartan and placebo in patients with HFrEF.
The effect of ACEI/ARB in preventing DM was similar to the results of previous large clinical studies and meta-analyses [5, 7, 36, 37, 46,47,48], i.e. ACEI/ARB treatment significantly reduced the incidence of new-onset diabetes. Furthermore, there were some additional findings in which ACEI treatment reduced the risk of new-onset DM among patients with not all-HF or with HFpEF, increased the risk of hypoglycaemia, and reduced diabetes complications among patients with not all-DM compared with placebo, with statistically significant differences. Also, ACEI/ARB treatment exerted positive effects on other research indicators. The above results suggested that ACEI/ARB also have a role in glycaemic control.
The differences in the subgroup results may be due to the differential effects of sacubitril/valsartan, ACEI/ARB treatment in patients with various background diseases, such as with or without HF and different types of HF. Currently, no progress has been made in studies of effective ways to treat HF and thus improve DM [4]. Therefore, it is difficult to explain our findings by the indirect therapeutic effect of sacubitril/valsartan on HF and thus on DM. Considering that the underlying cardiovascular diseases in patients with HF can lead to other metabolic and energetic disturbances closely related to DM [4, 67], we hypothesise that sacubitril/valsartan may have a relevant beneficial effect on DM by directly ameliorating these adverse pathophysiological alterations and thus have a more pronounced effect in patients with HF. The pathophysiological heterogeneity within the broader clinical spectrum of HFpEF, which may represent different progression or disease, may be involved in the different effects of neurohormone antagonists in patients with HFrEF and HFpEF. In addition, diabetes has different cardiovascular effects in patients with different types of HF [68, 69], resulting in the additional effects of sacubitril/valsartan, ACEI/ARB on DM [70].
We conducted a reasonable search of the literature and carefully screened the results using strict standards, which resulted in a large study sample size. This was the first meta-analysis of the effect of sacubitril/valsartan and comprehensive, updated analysis of the role of ACEI/ARB in patients with diabetes, which included only RCTs. Most of the studies in this analysis were large multi-centre clinical trials and most of our analyses were derived from the analysis of moderate to high-quality evidence. Hence, the quality of our meta-analysis was high. Our study confirmed the effect of sacubitril/valsartan and comprehensively analysed the role of ACEI/ARB in DM. Sodium-glucose cotransporter 2 inhibitor has become the only anti-diabetes drug that can reduce HF events, and our study may set the stage for whether sacubitril/valsartan or angiotensin-receptor/enkephalinase inhibitors could be used as anti-HF agents for the treatment of diabetes. However, several possible deficiencies should also be noted. Firstly, the metrics we studied were not the main objective of most of the trials, and the lack of clarity in the definitions and measurement of the metrics in most cases may have resulted in the application of different criteria, as well as bias, in our results. Secondly, no standardised definitions were used for HF, which also may have led to some bias in the subgroup analysis. Thirdly, most trials did not match patients and select dosages based on diabetes status, while studies using sacubitril/valsartan were primarily in people with HF, and studies using placebo were primarily in people with not all-HF, and the observation period of the individual studies was short.
The results of our study, especially in reducing glycaemia and new-onset DM, revealed that sacubitril/valsartan treatment had a positive effect on the control of glycaemia and the development of DM, and ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan. The above effects varied across disease settings and the evidence may have been the strongest in patients with HF. Hence, sacubitril/valsartan has the potential to become an anti-HF drug for the treatment of diabetes. However, the combined use of sacubitril/valsartan, ACEI, or ARB and conventional doses of diabetes medication may increase the incidence of hypoglycaemia and requires further studies. Dose adjustments of insulin or other antihyperglycaemic agents may be needed, especially in patients with HF. In conclusion, the effect, exact mechanism, and population that may benefit from sacubitril/valsartan treatment in DM need to be clarified by further studies. However, these results will bring more information and inspiration to the prevention and treatment of DM.
All the data used to generate this meta-analysis is publicly available, and the datasets used and analysed during the current study are available from the corresponding author on reasonable request.
Angiotensin-converting enzyme inhibitors
Angiotensin-receptor blockers
Renin-angiotensin-aldosterone system
Confidence interval
Diabetes mellitus
Grading of Recommendations Assessment, Development, and Evaluation
Heart failure
Natriuretic peptide
Placebo
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Randomised clinical trials
Revised Cochrane risk-of-bias tool for randomized trials
Relative risk
Sacubitril/valsartan
Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016;12(10):616–22. https://doi.org/10.1038/nrendo.2016.105.
Article Google Scholar
International Diabetes Federation. IDF Diabetes Atlas. 7th ed; 2016. http://www.diabetesatlas.org. Accessed 13 June 2022
Google Scholar
McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843–51. https://doi.org/10.1016/s2213-8587(14)70031-2.
Article Google Scholar
Cattadori G, Pantanetti P, Ambrosio G. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Res Clin Pract. 2019;157:107835. https://doi.org/10.1016/j.diabres.2019.107835.
Article Google Scholar
Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286(15):1882–5. https://doi.org/10.1001/jama.286.15.1882.
Article Google Scholar
Bangalore S, Messerli FH. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2007;356(5):522–4. https://doi.org/10.1056/NEJMc063077.
Article Google Scholar
Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112(1):48–53. https://doi.org/10.1161/circulationaha.104.528166.
Article Google Scholar
Barzilay JI, Gao P, Rydén L, et al. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011;34(9):1902–7. https://doi.org/10.2337/dc11-0545.
Article Google Scholar
Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–40. https://doi.org/10.1016/s2213-8587(17)30087-6.
Article Google Scholar
Wang CH, Leung N, Lapointe N, et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation. 2003;107(14):1923–9. https://doi.org/10.1161/01.Cir.0000062646.09566.Cc.
Article Google Scholar
Arbin V, Claperon N, Fournié-Zaluski MC, Roques BP, Peyroux J. Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol. 2003;41(2):254–64. https://doi.org/10.1097/00005344-200302000-00015.
Article Google Scholar
Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254–63. https://doi.org/10.1002/cpt.455.
Article Google Scholar
Campbell DJ. Long-term neprilysin inhibition – implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–86. https://doi.org/10.1038/nrcardio.2016.200.
Article Google Scholar
Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab. 2020;11:2042018820970444. https://doi.org/10.1177/2042018820970444.
Article Google Scholar
Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663–70. https://doi.org/10.1016/j.jchf.2014.09.001.
Article Google Scholar
Ruxin W, Haowen Y, Yongting Z, et al. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42022336311. Accessed 24 Nov 2022.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Article Google Scholar
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.
Article Google Scholar
Page MJ, Mckenzie JE, Kirkham J, Dwan K, Forbes A. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Db Syst Rev. 2014;10(10):MR000035.
Google Scholar
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.
Article Google Scholar
Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077–84. https://doi.org/10.1001/jama.2019.12843.
Article Google Scholar
Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens. 2019;21(1):67–76. https://doi.org/10.1111/jch.13437.
Article Google Scholar
Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–95. https://doi.org/10.1016/S0140-6736(12)61227-6.
Article Google Scholar
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. New Engl J Med. 2019;380(6):539–48. https://doi.org/10.1056/NEJMoa1812851.
Article Google Scholar
Tsutsui H, Momomura SI, Saito Y, et al. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction-results from the PARALLEL-HF study. Circ J. 2021;85(5):584–94. https://doi.org/10.1253/circj.CJ-20-0854.
Article Google Scholar
Pieske B, Wachter R, Shah SJ, et al. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919–29. https://doi.org/10.1001/jama.2021.18463.
Article Google Scholar
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.
Article Google Scholar
Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. JACC. 2019;74(23):2858–73. https://doi.org/10.1016/j.jacc.2019.09.063.
Article Google Scholar
Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138(15):1505–14. https://doi.org/10.1161/CIRCULATIONAHA.118.034818.
Article Google Scholar
Bicknell CD, Kiru G, Falaschetti E, Powell JT, Poulter NR. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur Heart J. 2016;37(42):3213–21. https://doi.org/10.1093/eurheartj/ehw257.
Article Google Scholar
Baker JV, Wolfson J, Collins G, et al. Losartan to reduce inflammation and fibrosis endpoints in HIV disease. Aids. 2021;35(4):575–83. https://doi.org/10.1097/qad.0000000000002773.
Article Google Scholar
Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928–38. https://doi.org/10.1056/NEJMoa1008816.
Article Google Scholar
Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67. https://doi.org/10.1056/NEJMoa0805450.
Article Google Scholar
Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151(1):11–20, w13-14. https://doi.org/10.7326/0003-4819-151-1-200907070-00120.
Article Google Scholar
Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86. https://doi.org/10.1007/s00125-011-2325-z.
Article Google Scholar
McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90. https://doi.org/10.1056/NEJMoa1001121.
Article Google Scholar
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–9.
Article Google Scholar
Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107(9):1291–6. https://doi.org/10.1161/01.cir.0000054611.89228.92.
Article Google Scholar
Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86. https://doi.org/10.1097/00004872-200305000-00011.
Article Google Scholar
Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–68. https://doi.org/10.1056/NEJMoa042739.
Article Google Scholar
Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117(1):24–31. https://doi.org/10.1161/circulationaha.106.685073.
Article Google Scholar
Piepoli MF, Hussain RI, Comin-Colet J, et al. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23(1):127–35. https://doi.org/10.1002/ejhf.2076.
Article Google Scholar
Vader JM, Givertz MM, Starling RC, et al. Tolerability of sacubitril/valsartan in patients with advanced heart failure: analysis of the LIFE Trial run-in. JACC Heart Fail. 2022;10(7):449–56. https://doi.org/10.1016/j.jchf.2022.04.013.
Article Google Scholar
NCT. Efficacy and safety of azilsartan medoxomil in African American participants with essential hypertension. 2011. https://clinicaltrials.gov/ct2/show/study/NCT00591253. Accessed 10 June 2022.
Google Scholar
NCT. Telmisartan to reduce AIDS-related fibrotic and inflammatory contributors (TRAFIC Study). 2021. https://clinicaltrials.gov/ct2/show/study/NCT01928927. Accessed 10 June 2022.
Google Scholar
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7. https://doi.org/10.1016/s0140-6736(07)60108-1.
Article Google Scholar
Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. JACC. 2005;46(5):821–6. https://doi.org/10.1016/j.jacc.2005.05.051.
Article Google Scholar
Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487–96. https://doi.org/10.1016/S1262-3636(07)70146-5.
Article Google Scholar
Morris AD, Boyle DI, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. Diabetes Care. 1997;20(9):1363–7. https://doi.org/10.2337/diacare.20.9.1363.
Article Google Scholar
Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44(5):513–8. https://doi.org/10.1046/j.1365-2125.1997.00615.x.
Article Google Scholar
Grégoire F, Pariente A, Fourrier-Reglat A, Haramburu F, Bégaud B, Moore N. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. Br J Clin Pharmacol. 2008;66(1):142–5. https://doi.org/10.1111/j.1365-2125.2008.03176.x.
Article Google Scholar
van der Zijl NJ, Moors CCM, Goossens GH, Hermans MMH, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care. 2011;34(4):845–51. https://doi.org/10.2337/dc10-2224.
Article Google Scholar
Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41(2):127–33. https://doi.org/10.1007/s001250050880.
Article Google Scholar
Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261–6. https://doi.org/10.2337/diacare.28.9.2261.
Article Google Scholar
Lazo M, Young JH, Brancati FL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62(9):3189–93. https://doi.org/10.2337/db13-0478.
Article Google Scholar
Jujić A, Nilsson PM, Engström G, Hedblad B, Melander O, Magnusson M. Atrial natriuretic peptide and type 2 diabetes development–biomarker and genotype association study. PLoS One. 2014;9(2):e89201. https://doi.org/10.1371/journal.pone.0089201.
Article Google Scholar
Everett BM, Cook NR, Chasman DI, et al. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin Chem. 2013;59(3):557–65. https://doi.org/10.1373/clinchem.2012.194167.
Article Google Scholar
Pfister R, Sharp S, Luben R, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8(10):e1001112. https://doi.org/10.1371/journal.pmed.1001112.
Article Google Scholar
Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012;97(2):638–45. https://doi.org/10.1210/jc.2011-2425.
Article Google Scholar
Coué M, Moro C. Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie. 2016;124:84–91. https://doi.org/10.1016/j.biochi.2015.05.017.
Article Google Scholar
Birkenfeld AL, Adams F, Schroeder C, Engeli S, Jordan J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension. 2011;57(2):e4–5. https://doi.org/10.1161/hypertensionaha.110.165159.
Article Google Scholar
Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122(3):1022–36. https://doi.org/10.1172/jci59701.
Article Google Scholar
Stanford KI, Middelbeek RJ, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 2013;123(1):215–23. https://doi.org/10.1172/jci62308.
Article Google Scholar
Birkenfeld AL, Boschmann M, Engeli S, et al. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One. 2012;7(8):e43238. https://doi.org/10.1371/journal.pone.0043238.
Article Google Scholar
Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53(22):2070–7. https://doi.org/10.1016/j.jacc.2009.02.038.
Article Google Scholar
Moro C, Klimcakova E, Lolmède K, et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia. 2007;50(5):1038–47. https://doi.org/10.1007/s00125-007-0614-3.
Article Google Scholar
Kerr M, Dodd MS, Heather LC. The ‘Goldilocks zone’ of fatty acid metabolism; to ensure that the relationship with cardiac function is just right. Clin Sci (Lond). 2017;131(16):2079–94. https://doi.org/10.1042/cs20160671.
Article Google Scholar
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71. https://doi.org/10.1016/j.jacc.2013.02.092.
Article Google Scholar
Lam CS, Lund LH. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart. 2016;102(4):257–9. https://doi.org/10.1136/heartjnl-2015-308852.
Article Google Scholar
Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559–73. https://doi.org/10.1038/s41569-020-0363-2.
Article Google Scholar
Download references
We would like to thank the participants and staff of the Clinicaltrials.gov for their contributions, because most of the data in the study came from this. Thanks to the staff and subjects who conducted these studies, they have promoted the progress of medicine.
This study was supported by the Funding by Science and Technology Projects in Guangzhou (Grant Number: 202201020081), National Natural Science Foundation of China (Grant Number: 82200417), and Talent Introduction Funding Project of The First Affiliated Hospital of Jinan University (Grant Number: 808026). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Ruxin Wang, Haowen Ye, and Yongting Zhao have contributed equally to this work and share first authorship.
Department of Endocrinology and Metabolism, The First Affiliated Hospital of Jinan University, No. 613, Huang pu Avenue West, Guangzhou, Guangdong, China
Ruxin Wang, Haowen Ye, Jinjing Wei, Ying Wang & Lihong Wang
Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Harbin, China
Yongting Zhao
Clinical Experimental Center, The First Affiliated Hospital of Jinan University, No. 613, Huang pu Avenue West, Guangzhou, Guangdong, China
Xiaofang Zhang
The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases, The First Affiliated Hospital, Jinan University, Guangzhou, China
Lihong Wang
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
RX and HW contributed to the conception and design of the study. LH and XF provided administrative support. RX, YW, and JJ applied the inclusion and exclusion criteria. Literature search and data extraction were done by RX and HW. RX, HW, and YT contributed to the assembly of data. RX, HW, and YT analysed and interpreted the data. RX, LH, and XF contributed to the writing of the report. All authors approved the final version of the report.
Correspondence to Xiaofang Zhang or Lihong Wang.
Every study included in the meta-analysis was published after ethics committee approval and each subject signed a written consent form. Therefore, no further ethics committee approval was required for this meta-analysis.
Consent for publication was obtained from all authors.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The review method registered in PROSPERO.
Search strategy in PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. Table S5. Eligibility criteria of included studies. Figure S1. Flow chart of literature search and study selection. Figure S2–S7. Network charts in network meta-analyses. Figure S8–S9. Funnel charts in direct comparisons. Figure S10–S20. Sensitivity analysis charts in direct comparisons. Figure S21-S25. Funnel charts in indirect comparisons.
PRISMA 2020 for Abstracts Checklist.
Methodological quality graph. Figure S2. Methodological quality summary. Figure S3-S33. Forest maps for all meta-analyses.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and Permissions
Wang, R., Ye, H., Zhao, Y. et al. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. BMC Med 20, 487 (2022). https://doi.org/10.1186/s12916-022-02682-w
Download citation
Received: 21 July 2022
Accepted: 28 November 2022
Published: 17 December 2022
DOI: https://doi.org/10.1186/s12916-022-02682-w
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Advertisement
ISSN: 1741-7015
By using this website, you agree to our Terms and Conditions, California Privacy Statement, Privacy statement and Cookies policy. Manage cookies/Do not sell my data we use in the preference centre.
© 2022 BioMed Central Ltd unless otherwise stated. Part of Springer Nature.